This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote
by Zacks Equity Research
FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More
by Zacks Equity Research
The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
by Zacks Equity Research
Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.
Lilly (LLY) Stock Riding on Pipeline Developments This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
by Zacks Equity Research
Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.
Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug
by Zacks Equity Research
Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.
Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm
by Zacks Equity Research
The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.
3 Biotech Stocks Poised to Gain in the Second Half of 2021
by Ekta Bagri
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.
Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status
by Zacks Equity Research
Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.
Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.
Cassava (SAVA) Stock Up on Alzheimer's Candidate Update
by Zacks Equity Research
Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
Here's Why Prothena (PRTA) Stock Is Up So Far This Month
by Zacks Equity Research
Prothena (PRTA) surges on the prospects of its Alzheimer's disease drug candidates, following Biogen???s AD drug approval.
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate
by Zacks Equity Research
Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.
Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight
by Sweta Jaiswal, FRM
The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.
Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug
by Zacks Equity Research
Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Should You Buy Biotech ETFs Now?
by Neena Mishra
Biotech stocks are rallying this month; can the trend continue?
Sage Stock Declines on Late-Stage Depression Study Data
by Zacks Equity Research
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.
Top-Performing Biotech ETFs of Last Week
by Sweta Killa
Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.
5 Best Leveraged ETFs of Last Week
by Sanghamitra Saha
We highlight a few leveraged ETF areas that won last week.
The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.
Top Research Reports for Intel, NextEra Energy & PetroChina
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), NextEra Energy (NEE), and PetroChina Company (PTR).